Sodium-potassium-chloride cotransporter type 2 (NKCC2) (NKCC2)

The diuretic effect via kidney/bladder pathways describes the pharmacological promotion of sodium and water excretion by the kidney, primarily through inhibition of key ion transporters (notably NKCC2 in the thick ascending limb of the loop of Henle for loop diuretics, and the sodium-chloride symporter in the distal convoluted tubule for thiazide diuretics). These molecular targets mediate sodium reabsorption, and their inhibition decreases blood volume and pressure, making them central in treating hypertension, heart failure, and edematous states. The term as originally supplied is non-specific and refers to a process, not a unique molecule or receptor, but the most relevant molecular target in this context is the sodium-potassium-chloride cotransporter type 2 (NKCC2).

Other names

Na-K-2Cl cotransporterSLC12A1 (gene encoding NKCC2)Loop diuretic targetSodium-chloride symporter (for distal tubule, thiazide diuretics)Epithelial sodium channel (ENaC)

Inhibition of sodium reabsorption in renal tubules (by blocking NKCC2 or sodium-chloride symporters or ENaC); Increased urinary sodium and water excretion, decreasing blood volume and pressure